EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model

Tao Wang, Michael P. Gantier, Dongxi Xiang, Andrew G. Bean, Matthew Bruce, Shu Feng Zhou, Mustafa Khasraw, Alister Ward, Li Wang, Ming Q. Wei, Hadi AlShamaileh, Lijue Chen, Xiaodong She, Jia Lin, Lingxue Kong, Sarah Shigdar, Wei Duan

Research output: Contribution to journalArticlepeer-review

86 Citations (Scopus)

Abstract

Understanding the molecular basis of drug resistance and utilising this information to overcome chemoresistance remains a key challenge in oncology. Here we report that survivin, a key protein implicated in drug resistance, is overexpressed in cancer stem cell pool of doxorubicin-resistant breast cancer cells. Moreover, by utilising an active targeting system consisting of an RNA aptamer targeted against the epithelial cell adhesion molecule and a Dicer substrate survivin siRNA, we could deliver a high dose of the siRNA to cancer stem cells in xenograft tumours. Importantly, silencing of survivin with this aptamer-siRNA chimera in cancer stem cell population led to the reversal of chemoresistance, such that combined treatment with low dose of doxorubicin inhibited stemness, eliminated cancer stem cells via apoptosis, suppressed tumour growth, and prolonged survival in mice bearing chemoresistant tumours. This strategy for in vivo cancer stem cell targeting has wide application for future effective silencing of anti-death genes and in fact any dysregulated genes involved in chemoresistance and tumour relapse.
Original languageEnglish
Pages (from-to)1456-1472
Number of pages17
JournalTheranostics
Volume5
Issue number12
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model'. Together they form a unique fingerprint.

Cite this